Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-label, Multi-centre Study to Assess the Efficacy and Safety of Intravitreal THR-317 for the Treatment of Macular Telangiectasia Type 1 (MacTel 1)

Trial Profile

A Phase 2, Open-label, Multi-centre Study to Assess the Efficacy and Safety of Intravitreal THR-317 for the Treatment of Macular Telangiectasia Type 1 (MacTel 1)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2019

At a glance

  • Drugs THR 317 (Primary)
  • Indications Retinal telangiectasis
  • Focus Therapeutic Use
  • Sponsors Oxurion
  • Most Recent Events

    • 19 Oct 2018 According to an Oxurion media release, initial results from this clinical study are anticipated towards the end of the second half of 2019.
    • 21 Sep 2018 New trial record
    • 20 Sep 2018 According to an Oxurion media release, first patient has been enrolled.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top